Average cost of care in year after ovarian cancer surgery around $100K

November 9, 2017

(HealthDay)—For women with ovarian cancer who underwent both surgery and adjuvant chemotherapy, the average medical expenditures are about $100,000 in the first year after surgery, according to a study published online Nov. 7 in Obstetrics & Gynecology.

Alexandra S. Bercow, M.D., from Columbia University College of Physicians and Surgeons in New York City, and colleagues conducted a of women with diagnosed from 2009 to 2012 who underwent both surgery and . Medical expenditures were estimated for a 12-month period beginning on the date of surgery; all payments, including out-of-pocket costs, were examined. Data were included for 5,031 women after exclusion of patients with incomplete insurance enrollment or coverage, those who did not undergo chemotherapy, and those with capitated plans.

The researchers found that during the first year after the index procedure, the median total medical expenditures per patient were $93,632. Inpatient services accounted for 37.8 percent in expenditures ($30,708); outpatient services for 58.3 percent ($52,700); and outpatient drug costs for 3.8 percent ($1,814). The median out-of-pocket expense was $2,998, which included $1,509, $589, and $351 for outpatient services, inpatient services, and outpatient drug costs, respectively.

"The average cost of care for women with ovarian cancer in the first year after surgery is approximately $100,000. Patients bear approximately 3 percent of these costs in the form of out-of-pocket expenses," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Explore further: New VTE often occurs during chemo in ovarian cancer

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

New VTE often occurs during chemo in ovarian cancer

May 11, 2017
(HealthDay)—For patients with ovarian cancer, new diagnosis of venous thromboembolism frequently occurs during neoadjuvant or adjuvant chemotherapy, according to a study published in the June issue of Obstetrics and Gynecology.

Surgery, chemo best for elderly with advanced ovarian cancer

December 29, 2015
(HealthDay)—Primary debulking surgery and chemotherapy in an optimal timeframe is associated with the longest survival time for elderly women with advanced ovarian cancer, according to a study published in the January issue ...

Five-year risk of repeat SUI, POP surgery less than 10 percent

May 23, 2017
(HealthDay)—For women undergoing surgery for stress urinary incontinence (SUI) and pelvic organ prolapse (POP), the risk of repeat procedures is less than 10 percent, with increased risks for older women and initial POP ...

Kidney disease patients have higher out-of-pocket costs than stroke and cancer patients

January 17, 2017
Patients who have chronic kidney disease but are not on dialysis have higher out-of-pocket healthcare expenses than even stroke and cancer patients, according to a study by researchers at Loyola University Chicago and Loyola ...

More women choose breast reconstruction after mastectomy

October 13, 2017
(HealthDay)—Over five years, the proportion of U.S. breast cancer patients opting for breast reconstruction after mastectomy grew by about two-thirds, a new government report shows.

Survival similar with debulking by laparotomy, laparoscopy

April 10, 2017
(HealthDay)—For women with epithelial ovarian cancer, three-year survival rates are similar for women undergoing debulking by laparotomy or laparoscopy, according to a study published in the May issue of Obstetrics & Gynecology.

Recommended for you

DNA 'webs' aid ovarian cancer metastasis, study reveals

December 19, 2018
Researchers from the University of Texas MD Anderson Cancer Center have discovered that ovarian cancer cells spread, or metastasize, to new tissue after being caught in DNA "webs" extruded by immune cells. The study, which ...

From eye drops to potential leukaemia treatment

December 19, 2018
An active ingredient in eye drops that were being developed for the treatment of a form of eye disease has shown promise for treating an aggressive form of blood cancer. Scientists at the Wellcome Sanger Institute, University ...

Two ways cancer resists treatment are actually connected, with one activating the other

December 18, 2018
Drugs that target BRAF and MEK in cancer have shown promise in treating a subset of melanoma that carries a mutation in the BRAF gene, but drug resistance usually emerges, reversing the benefit of these drugs and limiting ...

HPV discovery raises hope for new cervical cancer treatments

December 18, 2018
Researchers at the University of Virginia School of Medicine have made a discovery about human papillomavirus (HPV) that could lead to new treatments for cervical cancer and other cancers caused by the virus.

Vaccine, checkpoint drugs combination shows promise for pancreatic cancers

December 18, 2018
Researchers at the Johns Hopkins Kimmel Cancer Center discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, demonstrating a possible pathway for treatment of people ...

Researchers identify ways breast cancer avoids immune system detection

December 18, 2018
Recent breakthroughs in immunotherapy are making a huge difference in treating some forms of cancer, especially metastatic cancer. But breast cancer has proven a tricky foe for this new therapy, and an interdisciplinary team ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

thomasct
not rated yet Nov 09, 2017
See my comment under today's heading.. Cancer drug parity laws lower costs for many, but not everyone.. an learn how to prevent 98% and cure most, based on over 1/2million reproducible bio-resonance tests.by Dr H R Clark PhD ND.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.